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Until recently, the optimal medical treatment for the
prevention of infrainguinal bypass graft occlusion was a
matter of debate. Most Dutch vascular surgeons prescribed
oral anticoagulants,1 supported by a well-organized system
of thrombosis centers. In other countries, aspirin was the
most frequently used antithrombotic treatment.2
The recently performed Dutch Bypass Oral anticoag-
ulants or Aspirin (BOA) Study demonstrated beneficial
effects of oral anticoagulants with regard to the prevention
of venous bypass graft occlusion, whereas aspirin proved
to be more effective in the prevention of nonvenous graft
occlusion.3 Oral anticoagulant treatment prevented more
myocardial infarctions and ischemic strokes compared
with aspirin. On the other side, an increased risk of hem-
orrhagic complications was demonstrated in the patients
treated with oral anticoagulants. The target range of anti-
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coagulation, as recommended by the Federation of Dutch
Thrombosis Centers, was 3.0 to 4.5 international normal-
ized ratio (INR).4 Similar intensities, between 2.5 and 4.8
INR, had been used in other prevention trials in patients
after coronary bypass graft surgery, atrial fibrillation,
myocardial infarction, and cerebral ischemia.5-8 The opti-
mal intensity of anticoagulant treatment offers the best
risk-benefit ratio (ie, the optimal balance of ischemic and
hemorrhagic events). This optimum has been determined
for several indications: after myocardial infarction between
2.0 and 4.0 INR,7 after cerebral ischemia of cardiac origin
between 2.0 and 4.0 INR,6 and in patients with prosthetic
heart valves between 2.5 and 5.0 INR.9 For patients who
had cerebral ischemia of presumed arterial origin, antico-
agulation intensities with INR above 3.0 resulted in an
excess of bleeding complications.8
The exact date of most of the graft occlusions is
unknown, which makes this primary end point of the
Dutch BOA Study unsuitable for analysis of anticoagu-
lation intensity at the time of occlusion. The date of
onset of secondary outcome events, such as myocardial
infarction and hemorrhage, is exactly known. To deter-
mine the optimal intensity of oral anticoagulant treat-
ment in patients after infrainguinal bypass graft surgery,
we quantitatively analyzed the occurrence of arterial
thromboembolic and hemorrhagic events with respect
to the level of anticoagulation preceding the events in
1326 patients randomized to oral anticoagulant treat-
ment in the Dutch BOA Study.
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Objectives: The purpose of this study was to determine the optimal intensity of oral anticoagulation in patients who par-
ticipated in a randomized trial of oral anticoagulants or aspirin after infrainguinal bypass graft surgery.
Methods: The distribution of patient-time spent in international normalized ratio (INR) classes of 0.5 INR unit was cal-
culated assuming a linear change between successive measurements. INR-specific incidence rates of ischemic and hem-
orrhagic events were calculated as the ratio of the number of events at a certain INR category and the total patient-time
spent in that class. The relationship between INR class and event rates was quantified by rate ratios calculated in a
Poisson regression model.
Results: In 1326 patients (mean age, 69 years) 41,928 INR measurements were recorded in 1698 patient-years. Patients
spent 50% of the total time within the target range of 3.0 to 4.5 INR. Most of the patient-time (60%) was spent
between 2.5 and 3.5 INR. For each increasing class of 0.5 INR, the incidence of ischemic events (n = 154, INR data
on event available in 49%) decreased by a factor of 0.97 (95% CI, 0.87-1.08). The incidence of major bleeding (n =
123, INR data on event available in 65%) increased significantly by a factor of 1.27 (95% CI, 1.19-1.34) for each
increasing 0.5 INR category. The optimal target range was 3.0 to 4.0 INR, with an incidence of 3.8 events (0.9
ischemic and 2.9 hemorrhagic) per 100 patient-years.
Conclusions: The target range of 3.0 to 4.0 INR is the optimal range of achieved anticoagulation intensity and is safe
for the prevention of ischemic events in patients after infrainguinal bypass graft surgery. (J Vasc Surg 2001;33:522-7.)
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METHODS
Patients
All patients studied were included in the Dutch BOA
Study, a multicenter randomized trial to compare the
effectiveness of oral anticoagulants with that of aspirin in
preventing occlusions of infrainguinal bypass grafts and
other thrombotic events. Background, design, and results
of the trial have been reported elsewhere.3 The study was
approved by the ethics committees of all participating hos-
pitals and by the Dutch Health Insurance Council. All
patients who were enrolled in the study gave written
informed consent. Between April 1995 and March 1998,
1326 patients were randomized to oral anticoagulant
treatment. All patients who were receiving active treat-
ment were subjects of the current study, which resulted in
1698 patient-years of follow-up in the current study.
Anticoagulant treatment
Oral anticoagulant treatment consisted of phenpro-
coumon or acenocoumarol, depending on the surgeons’
preference. Calculation of dosage adjustment to achieve the
target INR of 3.0 to 4.5 was performed at the anticoagula-
tion clinics according to their own protocol. INR data of all
follow-up visits were reported to the BOA Trial Office.
Calculation of INR-specific events rates
Data on the occurrence of events (the numerator) and
data on patient-time spent in various categories of antico-
agulation intensity (the denominator) are required to cal-
culate INR-specific events rates.
Definition of events. The primary outcome event of
the Dutch BOA study was graft occlusion; secondary out-
come events were (vascular) death, nonfatal myocardial
infarction, nonfatal stroke, amputation, vascular interven-
tion, and major hemorrhage. The date of detection of
graft occlusion is not necessarily the true date of graft
occlusion. Unfortunately, this makes this end point
unsuitable for analysis of INR values at these presumed
dates of graft occlusion. For the current study we analyzed
data on the occurrence of vascular death, myocardial
infarction, stroke, and hemorrhage only, because the date
of onset of these events is exactly known. All of these
events (including sequential events in the same patients)
were eligible for the analysis.
Death from vascular disease included sudden death
(reliable observation of the time between onset of symp-
toms and death, or the patient was found dead) or death
from stroke, myocardial infarction, congestive heart fail-
ure, peripheral vascular disease, hemorrhage, or other vas-
cular causes. If no clear data on the cause of death were
available, the case was classified as vascular death.
Myocardial infarction was defined by at least two of the
following: a history of chest discomfort for at least half an
hour, specific cardiac enzyme levels more than twice the
upper limit of normal, or the development of new Q waves
on the standard 12-lead electrocardiogram. Stroke was
defined as focal neurologic deficit of sudden onset, per-
sisting for more than 24 hours, with an increase in handi-
cap of at least one grade on the modified Rankin scale.10,11
Findings from computed tomography brain scanning, if
performed, were recorded. Major hemorrhage included
fatal bleeding, intracranial hemorrhage, or any bleeding
requiring hospital attendance, regardless of interventions.
Postoperative bleedings (within 30 days after surgery)
were excluded from this analysis. Events were adjudicated
and classified by an independent panel of two neurolo-
gists, cardiologists, vascular internists, or vascular sur-
geons, who were unaware of treatment allocation.
Discrepancies were resolved with the involvement of a
third reviewer. If this resulted in three different classifica-
Fig 1. Distribution of patient-years spent in each INR unit. INR, International normalized ratio.
tions, consensus was reached through discussion. The
INR at the time of the occurrence of an event was
obtained from hospital records. If this INR measurement
was not performed or unavailable, we used the last INR
measured in the thrombosis center within 8 days before
the event. If this measurement was unavailable, the event
was excluded from the analysis.
Calculation of patient-time spent in various cate-
gories of anticoagulation intensity. The number of
patient-years is calculated by multiplying the number of
patients by the time of follow-up in years. The total patient-
time at different categories of INR was calculated assuming
a gradual linear change with increments of 1 day between
two measurements, with small steps of 0.1 INR. This
method has been described in detail by Rosendaal et al.12
Calculation of INR-specific event rates. The inci-
dence of events at various achieved intensities of anticoag-
ulation was calculated by dividing the number of events by
the total observation time with categories of 0.5 INR.
Statistical analysis
The precision of the event rate estimates was obtained
from a Poisson model and given as 95% CI. The Poisson
model was fitted to determine the relationship between
the intensity of anticoagulation (in categories of 0.5 INR)
and the incidence of thromboembolic and hemorrhagic
events. Data analysis was performed with EGRET statisti-
cal package (EGRET Software Corp, Seattle, Wash).13
RESULTS
From a total of 2650 randomized patients, 1326 were
allocated to oral anticoagulant treatment, with 2287
patient-years of follow-up. The mean age of the patients
allocated to oral anticoagulants was 69 years (range, 33-
93); 65% were male. The indication for surgery was inter-
mittent claudication in 50% of the patients and critical
ischemia in the other half. Eighty-one percent of all bypass
grafts were femoropopliteal, and 19% were femorocrural
or femoropedal. In 59%, an autologous vein was used for
bypass grafting; in the other patients a biograft, prosthesis,
or composite graft was used.
A total of 182 patients stopped taking their assigned
oral anticoagulant medication during follow-up. In the
current study, we analyzed 41,928 INR measurements in
an on-treatment period of 1698 patient-years. Patients
were monitored on average once per 2.1 weeks, resulting
in an average of 25 visits to the anticoagulation clinics per
year. Fig 1 shows the distribution of patient-years spent in
each INR category (0.5 INR unit). The INR was within
the target range of 3.0 to 4.5 approximately 50% of the
time. The intensity of anticoagulation was below the tar-
get range 39% of the time, whereas the intensity was above
the target range 11% of the time. Most patient-time (60%)
was spent within the range of 2.5 to 4.0 INR.
The incidence of first outcome events is shown in
Table I. There were 121 ischemic deaths, whereas there
were 16 fatal bleedings. The types of hemorrhage (includ-
ing repeated events) are shown in Table II.
A total of 154 ischemic and 123 hemorrhagic events
occurred during follow-up (this includes repeated events).
INR measurements within 8 days before the event were
available from 76 (49%) ischemic and 80 (65%) hemor-
rhagic events. The number of patient-years, events, and
INR-specific incidence rates of ischemic and hemorrhagic
events is given in Table III. The single INR category of
3.0 to 3.5 had the lowest incidence rate of combined
events: 3.3 events per 100 patient-years (95% CI, 1.8-5.7).
The incidence of ischemic and hemorrhagic events was 1.0
and 2.3, respectively, per 100 patient-years. The two INR
categories with the lowest incidence rates of both ischemic
and hemorrhagic events were from 3.0 to 4.0, with a total
incidence of 3.8 events (0.9 ischemic and 2.9 hemor-
rhagic) per 100 patient-years.
The INR-specific incidence rates of ischemic and hem-
orrhagic events are presented graphically in Fig 2. The
incidence of ischemic events hardly decreased with increas-
ing INR in the Poisson model: a factor of 0.97 (95% CI,
0.87-1.08) for each INR unit. The incidence of hemor-
rhage increased significantly for each 0.5 INR unit by a
factor of 1.27 (95% CI, 1.19-1.34). Fig 3 presents the
INR-specific incidence rates of all events, with the corre-
sponding 95% CIs.
DISCUSSION
The optimal intensity of oral anticoagulation with the
lowest incidence of ischemic and hemorrhagic events
appears to be between 3.0 and 4.0. In this range, the inci-
dence of ischemic events was low: 0.9 event per 100
patient-years. The incidence of hemorrhagic events was
higher when this level of anticoagulation was achieved: 2.9
bleeding complications per 100 patient-years. The inci-
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Table II. Types and total numbers of hemorrhage 
(number of fatalities)
Gastrointestinal 51 (5%)
Urinary tract 17 (0%)
Intracranial 18 (8%)
Other 33 (3%)
Total 119 (16%)
Table I. Occurrence of first ischemic and hemorrhagic
outcome events among the 1326 patients allocated to
oral anticoagulants
Death from ischemic causes 121
Death from hemorrhagic causes 16
Myocardial infarction (fatal and nonfatal) 29
Stroke (fatal and nonfatal) 35
Ischemic stroke 17
Hemorrhagic stroke 14
Undefined stroke (no CT scan available) 4
Hemorrhage (including intracranial) 108
CT, Computed tomography.
dence of all events was 3.8 per 100 patient-years at this
level of anticoagulation. The relative risk of ischemic
events decreased only 3% with each increasing INR unit,
whereas the incidence of bleedings increased markedly
with 27% per increasing INR unit.
The level of anticoagulation in patients with arterial
occlusive disease is still a matter of debate. Our findings
support the use of a target range of 3.0 to 4.0 INR. This
is in accordance with results of other studies performed to
determine optimal anticoagulant intensity. Two studies in
patients with atrial fibrillation and in patients after myocar-
dial infarction demonstrated optimal anticoagulation
intensity of 2.0 to 4.0 INR.6,7 The optimal intensity in
patients with mechanical heart valves was slightly higher,
between 2.5 and 5.0.9 These three studies were performed
in ways similar to ours.
Obviously, the gold standard to investigate the optimal
therapeutic range is a randomized trial. A limitation of such
a trial could be the inescapable fluctuation of intensity of
anticoagulation, caused by various patient characteristics
and extraneous factors, such as various methods of moni-
toring the intensity of anticoagulation. However, from a
pragmatic point of view, an intensity trial of high versus low
should be very well feasible. Also this way, the number of
graft occlusions in assigned treatment groups can be stud-
ied. The methods we used in the current study for calculat-
ing INR-specific incidence rates and the relationship
between incidence of events and intensity of anticoagulation
are useful for the assessment of the optimal therapeutic
range. The total number of patient-years of follow-up
(2287) was higher than the number of patient-years in
which we registered INR measurements (1698). This dif-
ference was caused by patients who discontinued their med-
ication and by missing INR measurements due to several
other reasons, mainly logistical. Unfortunately, data about
the level of anticoagulation were available in only 49% of the
ischemic events and in 65% of the bleedings. This was due
to the protocol of the trial, which did not require an INR
measurement at the time of an event. Obviously, at the time
of a bleeding, the level of anticoagulation is measured more
often than at the time of an ischemic event. These missing
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data cause an underestimation of the true incidences. This,
however, does not affect the result of estimation of optimal
anticoagulation intensity because the distribution of
patient-years and events over the INR units is not likely to
be changed by missing data. The missing data influence the
results only if there is an association with the INR level,
which is unlikely. We chose a strict criterion for the inclusion
of an event in the analysis. The last INR measure had to be
within a maximum of 8 days before the event; otherwise,
the event was excluded from the analysis of INR-specific
incidences of events. We think that measurements taken
more than 1 week before an event represent the INR at the
moment of the event insufficiently. Because of the smaller
numbers of patient-years in the lowest and highest levels of
anticoagulation, the estimated incidence rates of events at
these levels are not as precise as the incidence rates at the
levels between 2.0 and 4.5. The latter incidence rates, which
are the most precisely estimated, are the important ones,
given that the target ranges most often used vary between
these levels. The achieved anticoagulation intensity varied
most of the patient-time from 2.5 to 3.9 INR. Obviously,
safety with regard to bleeding complications was the goal
during the monitoring and administering of anticoagulant
therapy. Caution was probably stimulated because of the
advanced age of most of the patients.14 This caution
appeared to be legitimate because the risk of bleeding
increases sharply with a factor 1.27 for each increasing 0.5
INR category, whereas the risk of an ischemic event
increases only 3% with each decreasing category of 0.5 INR.
The increasing risk of ischemic events starts at anticoagula-
tion intensities below 3.0, whereas the risk of hemorrhagic
events begins to increase at INR levels above 3.5.
Regardless of possible differences in severity and risks of the
two types of events, we should attempt to achieve the low-
est incidence of both ischemic and hemorrhagic events, at
an anticoagulation level between 3.0 and 3.5 INR.
This large prospective study demonstrates that the opti-
mal intensity of anticoagulation is 3.0 to 3.5 INR. A target
range of 3.0 to 4.0 INR is safe with regard to hemorrhage
and effective with regard to the prevention of ischemic
events in patients with an infrainguinal bypass graft.
Table III. Incidence of ischemic and hemorrhagic events according to INR categories
Ischemic events Hemorrhagic events All events
INR Patient-years No. No./100 pt-yrs No. No./100 pt-yrs No. No./100 pt-yrs
< 2.0 150 23 15.4 9 6.0 32 21.4
2.0-2.4 187 11 5.9 5 2.7 16 8.5
2.5-2.9 318 15 4.7 8 2.5 23 7.2
3.0-3.4 390 4 1.0 9 2.3 13 3.3
3.5-3.9 301 2 0.7 11 3.7 13 4.3
4.0-4.4 167 3 1.8 11 6.6 14 8.4
4.5-4.9 87 2 2.3 7 8.0 9 10.3
5.0-5.4 41 4 9.9 5 12.3 9 22.2
5.5-5.9 21 3 14.3 0 0 3 14.3
≥ 6.0 37 9 24 15 41 24 65
Total 1698 76 5 80 5 156 9
We are indebted to professor H. Van Urk for his help-
ful comments on this article.
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